Instructions For Filling Out Form Fda 356H - Application To Market A New or Abbreviated New Drug or Biologic For Human Use

INSTRUCTIONS FOR FILLING OUT FORM FDA 356h – APPLICATION TO MARKET A NEW OR
ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE
(The field numbers below correspond to the numbered boxes on the Form FDA 356h)
NOTE: Please submit a new Form FDA 356h with each submission. Complete the pages of the form
sequentially using continuation pages as needed. If continuation pages are not needed, click on the
‘Remove Continuation Page’ button at top/bottom of form.
Field 1: Enter the date the submission is being submitted to the FDA. The date entered should match the date
of the cover letter for the submission.
Fields 2-6: APPLICANT INFORMATION

This section should include the name, street address, telephone and facsimile numbers of the person or legal
entity submitting the application. For biologic products, the name of applicant in Field 2 is the name of the
person or legal entity to whom the license will be issued. Enter the U.S. license number, if previously issued,
in the appropriate field. Enter the name, street address, and telephone number of the person or legal entity
authorized to represent a non-U.S. applicant in Field 6.
Fields 7-15: PRODUCT DESCRIPTION

This section should include all of the information necessary to identify the product that is the subject of this
application or submission.
Field 7: Provide the six-digit application number. For application numbers less than six-digits, the application
number should be preceded using zeros (i.e., for NDA 12345 enter 012345).
Field 8: Provide the four-digit supplement number with preceding zeros for supplement numbers that are less
than four-digits (i.e., for Supplement 1 enter 0001).
Field 15: For original and efficacy supplemental applications only (including resubmissions to these application
types), provide the indication(s) proposed within the application. Indicate if the proposed indication is for a
rare disease (prevalence <200,000 U.S. patients). Indicate if the product proposed within the application
(i.e. not the reference listed drug for an ANDA) has an FDA Orphan Drug Designation and if so; provide the
six-digit Orphan Designation number. If the submission is not an original application or efficacy supplement,
select ‘No’ in response to ‘Is this indication for a rare disease?’ Use the Continuation Page if there are more
than one proposed indications for use by adding one indication per entry and providing rare disease/Orphan
Drug Designation information for each entry, as applicable. If continuation pages are not needed, click on the
‘Remove Continuation Page’ button at top/bottom of form.
Fields 16-31: APPLICATION INFORMATION

Fields 16-18: Identify the appropriate application type.
Field 19: If the application is a 351(k) BLA, provide the name of the biological reference product that is the
basis for the application and the holder of the licensed application.
Field 20: If the application is an ANDA or 505(b)(2) NDA, provide the name of the reference listed drug
(ANDA) or listed drug(s) (505(b)(2) NDA) that is/are the basis for the application, the application number(s)
for the listed drug(s), and indicate what type(s) of patent certification or statement described under 21 CFR
314.50(i) is provided within the application.
Field 21: Select one of the submission types listed or specify the type of submission under “Other” if otherwise
not listed. See also 21 CFR 314.3(b).
Original: An application for which FDA has never issued an approval letter;
Labeling Supplement: A supplemental application for labeling changes to an approved product as
described under 21 CFR 314.70 and 21 CFR 601.12 that does not otherwise qualify as another type of
supplement (e.g., Efficacy, CMC, REMS);
FORM FDA 356h SUPPLEMENT (3/14) – FORM INSTRUCTIONS Page 1 of 3 PSC Publishing Services (301) 443-6740 EF
CMC Supplement: A supplemental application for chemistry, manufacturing, and control (CMC) changes
to an approved product as described under 21 CFR 314.70, 21 CFR 314.71, 21 CFR 314.72, and 21
CFR 601.12, including CMC supplements with corresponding labeling changes;
Efficacy Supplement: A supplemental application for changes to an approved product, including but
not limited to, a new indication, a new dosage regimen or route of administration, a comparative efficacy
claim naming another approved product, or a significant alteration in the patient population (e.g., a switch
of marketing status from prescription to over-the-counter), or labeling or manufacturing changes requiring
clinical data for approval;
Annual Report: See 21 CFR 314.81(b)(2) for NDAs and 21 CFR 601.12(d) for BLAs;
Product Correspondence: Any communication or general correspondence related to an application
(e.g., routine administrative changes, donor re-entry requests, lot distribution reports, license reissuance
requests, meeting requests) that is not an amendment to a pending application. Provide a description of
the content or intent of the Product Correspondence in Field 25 (Reasons for the Submission);
REMS Supplement: A supplemental application proposing a new Risk Evaluation and Mitigation
Strategy (REMS), REMS modification (including changes to a Medication Guide that is part of a REMS),
or submission of a REMS assessment;
Post Marketing Requirements or Commitments: A submission containing information related to post
marketing requirements or commitments (e.g., nonclinical protocol, final study report);
Periodic Safety Report: Periodic reports (Periodic Adverse Drug Experience Reports (PADERs)) of
adverse drug or biological product experience as described under 21 CFR 314.80(c)(2), 21 CFR 314.98,
and 21 CFR 600.80(c)(2), including those in Periodic Safety Update Report (PSUR) format;
Other (specify): State the submission type if it is not one of the previous submission types listed above
(e.g., formal dispute resolution request). If this box is checked, provide the Reasons for the Submission in
Field 25.
Field 22: Select one of the submission sub-types listed. See also 21 CFR 314.3(b).
Presubmission: Information submitted prior to the submission of a complete original application (e.g.,
submission of partial application (rolling submission);
Amendment: A submission to a pending original application, or pending supplemental application,
including responses to Information Request letters, Discipline Review letters, or other FDA
communications. Amendments also include submissions that contain additional supportive material
intended to augment or revise information previously submitted in a submission type listed under Field
21 (e.g., amendment to an annual report);
Initial submission: A submission type under Field 21 that has never before been submitted (excluding
presubmissions);
Resubmission: A complete response to an action letter, or submission of an original application that has
been the subject of a withdrawal before FDA action or a refusal to file action.
Field 23: Select the appropriate type of supplemental application, if applicable.

CBE (Changes Being Effected): A supplemental application proposing certain changes for which
distribution of the product made using the change(s) can occur upon FDA receipt of the application as
described under 21 CFR 314.70(c)(6) and 21 CFR 601.12(c)(5);
CBE-30 (Changes Being Effected in 30 Days): A supplemental application proposing certain changes
requiring submission at least 30 days prior to distribution of the product made using the change(s) as
described under 21 CFR 314.70(c) and 21 CFR 601.12(c);
Prior Approval (PA): A supplemental application proposing a major change for which distribution of
the product made using the change(s) cannot occur prior to FDA approval as described under 21 CFR
314.70(b) and 21 CFR 601.12(b).
FORM FDA 356h SUPPLEMENT (3/14) – FORM INSTRUCTIONS Page 2 of 3

Field 24: If the submission identified in Field 21 of this form contains data only from pediatric studies, select
‘Yes’. If the submission does not contain data from pediatric studies, or is an original application or efficacy
supplement that contains data from both adult and pediatric studies, select ‘No’.
Field 25: This section should contain a brief explanation of the contents of, or rationale for, the submission
(e.g., “manufacturing change from roller bottle to cell factory” or “response to Information Request Letter of
mm/dd/yy” or “pediatric exclusivity determination request” or “to fulfill a Subpart H postmarketing requirement”).
Field 26: Select the appropriate Proposed Marketing Status.
Field 27: Indicate whether the submission contains only Paper, both Paper and Electronic, or only Electronic
Media (e.g., electronic media or electronic submissions sent via the Electronic Submissions Gateway (ESG)).
Field 28: Enter the number of volumes, including electronic media, contained in the archival copy of this
submission.
Field 29: For original (initial) applications, efficacy supplements, CMC supplements, and
resubmissions to these submission types, this section should include complete information on
the locations of all manufacturing, packaging, and control sites for both drug substance and
drug product. For presubmissions and amendments to these submission types, complete establishment
information should be provided in this section when applicable (e.g., an amendment that describes changes
to previously submitted establishment information; an amendment that adds or removes an establishment;
a presubmission that includes CMC information including establishment information). For each site, please
include the establishment name, address, registration (FEI) number, Master File (MF; Drug Master File (DMF)
or Biologic Master File (BMF)) number (for facilities used under a MF), and establishment DUNS number.
Indicate whether or not the establishment is new to the application; new establishments will have by default a
‘pending’ status. If it is not a new establishment, indicate its current status (e.g., active, inactive, or withdrawn)
in the appropriate box. Also provide the name, address, phone number, fax number and email address for the
contact at the site. In the section “Manufacturing Steps, and/or Type of Testing”, provide a brief description
of the specific manufacturing steps and/or type of testing (e.g., final dosage form, stability testing) conducted
at the site (i.e., describe the type(s) of assays or testing completed). Indicate whether the site is ready for
inspection, or if not, when it will be ready.
Please note that, when applicable, the complete establishment description is requested under Field 31, item
15.
Use the Continuation Page as needed. If continuation pages are not needed, click on the ‘Remove
Continuation Page’ button at top/bottom of form.
Field 30: This section should contain a list of all Biologics License Applications (BLAs), Investigational New
Drug Applications (INDs), New Drug Applications (NDAs), Premarket Approval Applications (PMAs), Premarket
Notifications (510(k)(s), Investigational Device Exemptions (IDEs), and/or DMFs/BMFs that are cross-
referenced in the current application. Use the Continuation Page as needed. If continuation pages are not
needed, click on the ‘Remove Continuation Page’ button at top/bottom of form.
Field 31: This section contains items 1 through 20 which is a checklist that should be used to indicate the
types of information contained within a particular application or submission. Check all that apply. A complete
index or table of contents should immediately follow the Form FDA 356h and, if applicable, a User Fee Cover
Sheet (Forms FDA 3397, 3792, or 3794). Note that the CFR references are provided for most items in order
to indicate what type of information should or must be submitted in each section. For further information, the
applicant may consult the guidance documents that are available from the Agency.
Fields 32-39: CERTIFICATION

Enter the name and title, telephone number, facsimile number, email address, and street address of
the applicant’s Responsible Official in Fields 32-37 of the form. This person is responsible for certifying
compliance with applicable laws and regulations. The authorized U.S. agent named in Field 6 of the form may
also act as the applicant’s Responsible Official. The form must be signed in Field 38 by the applicant, or the
applicant’s attorney, agent, or other authorized official. 21 CFR 601.2(a). If the person signing the form in Field
38 does not reside or have a place of business within the United States, the form must be countersigned in
Field 39 by an attorney, agent, or other authorized official who resides or maintains a place of business within
the United States. 21 CFR 314.50(a)(5).
FORM FDA 356h SUPPLEMENT (3/14) – FORM INSTRUCTIONS Page 3 of 3

Instructions For Filling Out Form Fda 356H - Application To Market A New or Abbreviated New Drug or Biologic For Human Use

Uploaded by

Copyright:

Available Formats

Instructions For Filling Out Form Fda 356H - Application To Market A New or Abbreviated New Drug or Biologic For Human Use

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Instructions For Filling Out Form Fda 356H - Application To Market A New or Abbreviated New Drug or Biologic For Human Use

Uploaded by

Copyright:

Available Formats

INSTRUCTIONS FOR FILLING OUT FORM FDA 356h – APPLICATION TO MARKET A NEW OR

ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE

Fields 2-6: APPLICANT INFORMATION

Fields 7-15: PRODUCT DESCRIPTION

Fields 16-31: APPLICATION INFORMATION

Field 23: Select the appropriate type of supplemental application, if applicable.

FORM FDA 356h SUPPLEMENT (3/14) – FORM INSTRUCTIONS Page 2 of 3

Fields 32-39: CERTIFICATION

FORM FDA 356h SUPPLEMENT (3/14) – FORM INSTRUCTIONS Page 3 of 3

You might also like